Should a patient planning to conceive discontinue her statin therapy, and what safe lipid‑lowering alternatives are recommended during preconception and pregnancy?

Discontinue Statins Before Conception

Women planning pregnancy should discontinue statin therapy at least 1 month (preferably 3 months) before attempting conception, with bile acid sequestrants being the only approved lipid-lowering alternative during pregnancy if treatment is necessary 1.

Risk-Stratified Approach to Discontinuation

Standard Risk Patients (Primary Prevention)

• Discontinue statins immediately when planning conception or if already pregnant
• This includes women with:
  • Diabetes
  • Elevated 10-year ASCVD risk
  • LDL-C ≥190 mg/dL (including heterozygous familial hypercholesterolemia)
• Resume therapy only after completing breastfeeding 1

Very High-Risk Patients (Requires Individual Discussion)

For women with established ASCVD, multiple risk factors, or homozygous familial hypercholesterolemia, discuss continuing statin therapy with the patient, weighing the risk of cardiovascular events against theoretical fetal risks 1. Recent large observational studies have not demonstrated evidence of harm to mother or fetus with statin use 1, and meta-analyses show no significant increase in birth defects, including cardiac anomalies 2.

Safe Lipid-Lowering Alternatives During Pregnancy

First-Line Option

• Bile acid sequestrants (BAS): Only officially approved lipid-lowering therapy during pregnancy 1, 3
  • Critical caveat: Monitor for vitamin K deficiency in pregnant patients on BAS 1

Second-Line Considerations (Risk-Benefit Decision)

• Ezetimibe: Use only if potential benefit justifies fetal risk; no adequate controlled studies in pregnancy 1, 3
• Fenofibrate: Consider if benefits outweigh potential risks 3, 4

Contraindicated/Not Recommended

• Bempedoic acid: Discontinue when pregnancy recognized unless benefits outweigh risks 1
• PCSK9 inhibitors (evolocumab, alirocumab): No safety data; consider only before and after pregnancy 3
• Inclisiran: Discontinue when pregnancy recognized; may cause fetal harm based on mechanism of action 1
• Evinacumab: May cause fetal harm; pregnancy test recommended before starting; use effective contraception during treatment and 5 months after last dose 1

Clinical Management Algorithm

Step 1: Identify cardiovascular risk category

• Primary prevention → Discontinue statins
• Very high-risk/established ASCVD → Individualized discussion

Step 2: Timing of discontinuation

• Ideally 3 months before conception
• Minimum 1 month before conception
• Immediately if already pregnant (except very high-risk cases)

Step 3: Alternative therapy selection

• If lipid-lowering needed → Bile acid sequestrants
• Monitor vitamin K levels if using BAS
• Intensive lifestyle modifications for all patients

Step 4: Monitoring during pregnancy

• Recognize that progressive rise in LDL-C and triglycerides is physiologic during pregnancy 1
• Monitor for significant elevations requiring intervention

Important Caveats

The traditional contraindication of statins in pregnancy was based primarily on animal studies and case reports 4, 2. Recent evidence challenges this absolute contraindication: systematic reviews and meta-analyses show no clear association between statin use and birth defects 2, and pravastatin is being studied for pre-eclampsia prevention in high-risk women 1, 5.

However, adequate contraception is essential for women of reproductive age taking statins 6, as the precautionary principle still guides clinical practice despite evolving evidence.

Human clinical trials are currently in progress to determine whether hydrophilic statins (particularly pravastatin) may prevent pre-eclampsia through pleiotropic effects including anti-inflammatory, antioxidant, and endothelial protective mechanisms 1, 5.